PhaseBio Pharmaceuticals, Inc. – NASDAQ:PHAS

Add to watchlist

$0.07

+0.05

+312.35%

Market closed

Open in about 10 hours

-75.75%

month

-98.01%

quarter

-99.33%

year

Market Cap	N/A
Enterprise value	1.01M

P/E	-0.02
EV/Sales	-0.10
EV/EBITDA	0.03
Price/Sales	-0.34
Price/Book	-0.02
PEG ratio	N/A
EPS	0.59

Revenue	818K
EBITDA	28.16M
Income	27.83M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	-280.94%
Oper. margin	1041.79%
Gross margin	-2.08%
EBIT margin	1041.79%
EBITDA margin	3443.23%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS): Profit margin
Sep 2021	335K	-31.92M	-9529.55%
Dec 2021	158K	87.82M	55588.56%
Mar 2022	117K	-11.28M	-9648.72%
Jun 2022	208K	-16.78M	-8067.79%

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS): Earnings per share (EPS)
2022-05-16	-0.66	-0.23
2022-08-12	-0.31	-0.34

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS): Debt to assets
Sep 2021	77725000	128.05M	164.75%
Dec 2021	60540000	153.57M	253.67%
Mar 2022	38664000	141.05M	364.83%
Jun 2022	22166000	139.56M	629.63%

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS): Cash Flow
Sep 2021	-6.13M	-638K	-1.32M
Dec 2021	-19.99M	-1.65M	7.09M
Mar 2022	-22.88M	-49K	-179K
Jun 2022	-10.41M	-58K	-415K

PhaseBio Pharmaceuticals alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

PhaseBio Pharmaceuticals
Employees

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS): Employee count
Aug 2023	60
Sep 2023	60
Oct 2023	60
Nov 2023	60
Dec 2023	60
Jan 2024	60
Feb 2024	60
Mar 2024	60
Apr 2024	60
May 2024	60
Jun 2024	60
Jul 2024	60

PhaseBio Pharmaceuticals
Insider Trading

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS): Insider trades (number of shares)
Period	Buy	Sel
Nov 2021	0	5766
May 2022	0	11248
Oct 2022	0	1784109

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	19 May 2023	VAN DEN BROEK RICHARD director director	Restricted Stock Units	3,750	N/A	N/A
Option	19 May 2023	THORP CLAY director director	Common Stock	3,750	N/A	N/A
Option	19 May 2023	THORP CLAY director director	Restricted Stock Units	3,750	N/A	N/A
Option	19 May 2023	HUMPHRIES WILLIAM D. director director	Common Stock	2,538	N/A	N/A
Option	19 May 2023	HUMPHRIES WILLIAM D. director director	Restricted Stock Units	2,538	N/A	N/A
Option	19 May 2023	HARRIGAN EDMUND director director	Common Stock	3,750	N/A	N/A
Option	19 May 2023	SAPIR ALEX director director	Common Stock	3,750	N/A	N/A
Option	19 May 2023	HUTSON NANCY J director director	Restricted Stock Units	3,750	N/A	N/A
Option	19 May 2023	HUTSON NANCY J director director	Common Stock	3,750	N/A	N/A
Option	19 May 2023	HARRIGAN EDMUND director director	Restricted Stock Units	3,750	N/A	N/A

PHAS insider trading transactions

PhaseBio Pharmaceuticals
Patents

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Methods and compositions for treating muscle disease and disorders Filling date: 22 Jun 2020 Issue date: 8 Mar 2022	22 Jun 2020	8 Mar 2022
Application	Application METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS Filling date: 1 Jul 2021 Issue date: 27 Jan 2022	1 Jul 2021	27 Jan 2022
Application	Application METALLOENZYME INHIBITOR COMPOUNDS Filling date: 31 Aug 2021 Issue date: 13 Jan 2022	31 Aug 2021	13 Jan 2022
Application	Application METHODS OF REVERSING TICAGRELOR ACTIVITY Filling date: 20 Sep 2019 Issue date: 11 Nov 2021	20 Sep 2019	11 Nov 2021
Application	Application METALLOENZYME INHIBITOR COMPOUNDS Filling date: 17 Jun 2021 Issue date: 21 Oct 2021	17 Jun 2021	21 Oct 2021
Grant	Grant Utility: Metalloenzyme inhibitor compounds Filling date: 17 Jan 2020 Issue date: 5 Oct 2021	17 Jan 2020	5 Oct 2021
Grant	Grant Utility: Methods and compositions for treating cystic fibrosis Filling date: 8 May 2015 Issue date: 6 Jul 2021	8 May 2015	6 Jul 2021
Grant	Grant Utility: Metalloenzyme inhibitor compounds Filling date: 7 Sep 2018 Issue date: 22 Jun 2021	7 Sep 2018	22 Jun 2021
Application	Application METHODS AND COMPOSITIONS FOR TREATING MUSCLE DISEASE AND DISORDERS Filling date: 22 Jun 2020 Issue date: 11 Mar 2021	22 Jun 2020	11 Mar 2021
Grant	Grant Utility: Use of modified vasoactive intestinal peptides in the treatment of hypertension Filling date: 26 Sep 2016 Issue date: 9 Mar 2021	26 Sep 2016	9 Mar 2021

PHAS patents

PhaseBio Pharmaceuticals
Executives

Insider	Age	Compensation
Mr. Jonathan P. Mow (1965) Pres, Chief Executive Officer & Director	60	$812,440
Dr. John S. Lee (1968) Chief Medical Officer	57	$582,230
Mr. John P. Sharp (1965) Chief Financial Officer	60	$516,420

PhaseBio Pharmaceuticals
Latest News

Monday, 24 October 2022
08:00	PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code	businesswire.com
08:00	PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code	businesswire.com
Monday, 17 October 2022
19:41	These Were The Five Best And Worst Performing Healthcare Stocks In September 2022	24/7 Wall Street
Friday, 12 August 2022
11:17	PhaseBio Pharmaceuticals (PHAS) Reports Q2 Loss, Lags Revenue Estimates	Zacks Investment Research
Monday, 16 May 2022
08:17	PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates	Zacks Investment Research
Tuesday, 21 December 2021
12:43	PhaseBio Pulls Plug On Mid-Stage Hypertension Asset	Benzinga
Monday, 15 November 2021
14:32	PhaseBio's Shares Slide As Antiplatelet Candidate Shows Higher Rates Of Side Effect	Benzinga
Wednesday, 10 November 2021
18:19	PhaseBio Pharmaceuticals (PHAS) Reports Q3 Loss, Lags Revenue Estimates	Zacks Investment Research
Wednesday, 3 November 2021
10:10	PhaseBio's Bentracimab Reverses Ticagrelor-Associated Antiplatelet Activity In Mid-Stage Study	Benzinga
Sunday, 31 October 2021
10:30	5 Penny Stocks To Watch For November With Potential Biotech Catalysts	PennyStocks
Thursday, 7 October 2021
12:11	Do Options Traders Know Something About PhaseBio Pharmaceuticals (PHAS) Stock We Don't?	Zacks Investment Research
Tuesday, 31 August 2021
16:00	PhaseBio Pharmaceuticals to Present at 23rd Annual H.C. Wainwright Global Investment Conference	Business Wire

Ideas & Opinions

Seeking Alpha 16 Aug 2021

Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal
Seeking Alpha 15 Aug 2021

ViacomCBS: Now Is The Time To Buy

Frequently Asked Questions (FAQ)

What's the price of PhaseBio Pharmaceuticals stock today?

One share of PhaseBio Pharmaceuticals stock can currently be purchased for approximately $0.07.
When is PhaseBio Pharmaceuticals's next earnings date?

Unfortunately, PhaseBio Pharmaceuticals's (PHAS) next earnings date is currently unknown.
Does PhaseBio Pharmaceuticals pay dividends?

No, PhaseBio Pharmaceuticals does not pay dividends.
What is PhaseBio Pharmaceuticals's stock symbol?

PhaseBio Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "PHAS".
What is PhaseBio Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of PhaseBio Pharmaceuticals?

Shares of PhaseBio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are PhaseBio Pharmaceuticals's key executives?
PhaseBio Pharmaceuticals's management team includes the following people:
- Mr. Jonathan P. Mow Pres, Chief Executive Officer & Director(age: 60, pay: $812,440)
- Dr. John S. Lee Chief Medical Officer(age: 57, pay: $582,230)
- Mr. John P. Sharp Chief Financial Officer(age: 60, pay: $516,420)
How many employees does PhaseBio Pharmaceuticals have?

As Jul 2024, PhaseBio Pharmaceuticals employs 60 workers.
When PhaseBio Pharmaceuticals went public?

PhaseBio Pharmaceuticals, Inc. is publicly traded company for more then 6 years since IPO on 18 Oct 2018.
What is PhaseBio Pharmaceuticals's official website?

The official website for PhaseBio Pharmaceuticals is phasebio.com.
Where are PhaseBio Pharmaceuticals's headquarters?

PhaseBio Pharmaceuticals is headquartered at 1 Great Valley Pkwy Ste 30, Malvern, PENNSYLVANIA.
How can i contact PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals's mailing address is 1 Great Valley Pkwy Ste 30, Malvern, PENNSYLVANIA and company can be reached via phone at +1 610 981 6500.

PhaseBio Pharmaceuticals, Inc.

phasebio.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

+1 610 981 6500

1 Great Valley Pkwy Ste 30
Malvern, PENNSYLVANIA 19355

CIK: 0001169245
ISIN: US7172241090
CUSIP: 717224109